A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Phase 1

Recruiting

• Conditions: Primary Membranous Nephropathy
• Interventions: Drug: B007

• Registration Number: NCT05668403
• Lead Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd

Brief Summary

This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-12-12
• Study First Submitted QC: 2022-12-20
• Study First Posted: 2022-12-29
• Study Start: 2023-03-02
• Status Verified: 2025-01
• Last Update Submitted: 2025-02-07
• Last Update Posted: 2025-02-10
• Primary Completion: 2026-12-30
• Study Completion: 2027-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

1. Subjects who have fully understood this study and voluntarily signed the informed consent form;
2. Male or female subjects, aged between 18 and 75 years;
3. Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy;
4. Subjects with systolic blood pressure ≤ 140 mmHg and diastolic blood pressure ≤ 90 mmHg at screening;
5. If taking ACEI(Angiotensin converting enzyme inhibitors), ARB(Angiotensin receptor blocker), a stable dose within 4 weeks before screening is required;
6. Subjects who are able to follow the study protocol as judged by the investigator.

Exclusion Criteria

1. Subjects with secondary membranous nephropathy;
2. Subjects with uncontrolled blood pressure as judged by the investigator within 3 months before screening;
3. Subjects with decreases in urine protein ≥ 50% within 6 months before screening;
4. Subjects who have received or are receiving renal replacement therapy;
5. Subjects with type 1 diabetes mellitus, or those with type 2 diabetes mellitus who are diagnosed as diabetic nephropathy by percutaneous renal biopsy;
6. Subjects who have a clear history of tuberculosis or have received anti-tuberculosis treatment;
7. Subjects with active bacterial, viral, fungal, mycobacterial, parasitic or other infections requiring systemic antibiotics or antiviral therapy;
8. Subjects with known history of severe allergic reactions to humanized monoclonal antibodies；
9. Subjects who received live vaccination, major surgery, or participated in other clinical trials within 28 days before receiving the study drug;
10. Pregnant or lactating women; women of childbearing potential who have not been sterilized do not agree to use appropriate contraceptive measures during treatment and for at least 12 months after the last dose of the study drug;
11. Subjects with serious, progressive, or uncontrolled disease that may increase risks during the participation in the study as assessed by the investigator;
12. Subjects with a history of alcoholism or drug abuse within 12 months;
13. Subjects with positive hepatitis B surface antigen; those with positive hepatitis C virus antibody; those with a history of immunodeficiency;
14. Subjects with CD4+ T lymphocyte count < 300 cells/μL;
15. Other conditions unsuitable for participation in this study determined by the Investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
B007:1000mg	B007	B007: 1000mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
B007:350mg	B007	B007:350mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
B007:700mg	B007	B007: 700mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

Primary Outcome Measures

Name	Time	Method
Dose limiting toxicity（DLT）	Approximately 1 years	Adverse reactions that are certainly or possibly related to the drug being tested during the dose escalation phase.
Security: Incidence of Treatment-Emergent Adverse Events	Approximately 2 years	Adverse event type, incidence, duration, correlation with study drug

Secondary Outcome Measures

Name	Time	Method
Immunogenicity	Approximately 1 years	Incidence of ADA(Adenosine deaminase)
Biomarkers	Approximately 1 years	Changes in serum anti-PLA2R(Antiphospholipase A2 receptor) antibody levels relative to baseline
Dynamics of pharmacodynamics	Approximately 1 years	Changes of peripheral blood CD19+B cells(B-lymphocyte antigen CD19) relative to baseline
PK (Pharmacokinetics)	Approximately 1 years	AUC0-last（Area Under Curve of 0-last）
Proportion of subjects achieving clinical remission	Approximately 2 years	Proportion of subjects achieving clinical remission

Trial Locations

Locations (5)

Longhua Hospital Shanghai University of Traditional Chinese Medicine; 🇨🇳 Shanghai, China

The First Affiliated Hospital of Zhengzhou University; 🇨🇳 Zhengzhou, Henan, China

Hebei General Hospital; 🇨🇳 Shijiazhuang, Hebei, China

The First Affiliated Hospital,College of Medicine,Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China

Peking university first hospital; 🇨🇳 Beijing, China